Hologic, Inc. (NASDAQ:HOLX) Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,558,040 shares of the medical equipment provider's stock after purchasing an additional 82,661 shares during the period. DekaBank Deutsche Girozentrale owned 0.69% of Hologic worth $94,252,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HOLX. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Hologic in the 4th quarter worth approximately $4,215,000. Raymond James Financial Inc. purchased a new stake in shares of Hologic in the 4th quarter worth approximately $27,007,000. PNC Financial Services Group Inc. grew its stake in shares of Hologic by 5.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 39,014 shares of the medical equipment provider's stock worth $2,813,000 after buying an additional 1,853 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Hologic by 2.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 364,776 shares of the medical equipment provider's stock valued at $26,297,000 after purchasing an additional 10,049 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HOLX. Raymond James Financial reiterated an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI increased their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday. Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada decreased their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $78.75.

Insider Buying and Selling

In other news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Down 1.7%

HOLX stock traded down $1.13 during midday trading on Friday, hitting $65.72. The company's stock had a trading volume of 1,776,763 shares, compared to its average volume of 2,384,898. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market capitalization of $14.65 billion, a P/E ratio of 27.73, a PEG ratio of 2.41 and a beta of 0.55. The firm has a 50-day simple moving average of $61.32 and a 200-day simple moving average of $63.59.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $1.03 EPS. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.